Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency

Journal of Biological Chemistry

Volumn 287, Issue 45, 2012, Pages 38265-38278

  Bouchecareilh, Marion ^a   Hutt, Darren M ^a   Szajner, Patricia ^a   Flotte, Terence R ^b   Balch, William E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNCTIONAL FORMS; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACIDS;

ORGANIC ACIDS; PHYSIOLOGY;

ENZYME INHIBITION;

ALPHA 1 ANTITRYPSIN; SERINE PROTEINASE INHIBITOR; VORINOSTAT;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN SECRETION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; WILD TYPE;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CALNEXIN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM; GENE EXPRESSION; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; LIVER; MEMBRANE GLYCOPROTEINS; MUTATION; OXIDOREDUCTASES; PROTEIN FOLDING; PROTEIN TRANSPORT; PROTEOSTASIS DEFICIENCIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84868334619     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.404707     Document Type: Article

References (111)

1. Balch, W. E., Morimoto, R. I., Dillin, A., and Kelly, J. W. (2008) Adapting proteostasis for disease intervention. Science 319, 916-9199
2. Bouchecareilh, M., and Balch, W. E. (2011) Proteostasis. A new therapeutic paradigm for pulmonary disease. Proc. Am. Thorac. Soc. 8, 189-1955
3. Hutt, D., and Balch, W. E. (2010) Cell Biology. The proteome in balance. Science 329, 766-7677
4. Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., and Balch, W. E. (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959-9911
5. Ong, D. S., and Kelly, J. W. (2011) Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases. Curr. Opin. Cell Biol. 23, 231-2388
6. Gidalevitz, T., Prahlad, V., and Morimoto, R. I. (2011) The stress of protein misfolding. From single cells to multicellular organisms. Cold Spring Harb. Perspect. Biol. 3, a0097044
7. Balch, W. E., Roth, D. M., and Hutt, D. M. (2011) Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb. Perspect. Biol. 3, a0044999
8. Roth, D. M., and Balch, W. E. (2011) Modeling general proteostasis. Proteome balance in health and disease. Curr. Opin. Cell Biol. 23, 126-1344
9. Taylor, R. C., and Dillin, A. (2011) Aging as an event of proteostasis collapse. Cold Spring Harb. Perspect. Biol. 3, a0044400
10. Määttänen, P., Gehring, K., Bergeron, J. J., and Thomas, D. Y. (2010) Protein quality control in the ER. The recognition of misfolded proteins. Semin. Cell Dev. Biol. 21, 500-5111
11. Walter, P., and Ron, D. (2011) The unfolded protein response. From stress pathway to homeostatic regulation. Science 334, 1081-10866
12. Morimoto, R. I. (2008) Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev. 22, 1427-14388
13. Akerfelt, M., Morimoto, R. I., and Sistonen, L. (2010) Heat shock factors. Integrators of cell stress, development, and lifespan. Nat. Rev. Mol. Cell Biol. 11, 545-5555
14. Perlmutter, D. H. (2011) α1-Antitrypsin deficiency. Importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu. Rev. Med. 62, 333-3455
15. Kroemer, G., Mariño, G., and Levine, B. (2010) Autophagy and the integrated stress response. Mol. Cell 40, 280-2933
16. Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., and Sweet, M. J. (2011) Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 32, 335-3433
17. Malhi, H., and Kaufman, R. J. (2011) Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795-8099
18. Kitamura, M. (2011) Control of NF-κB and inflammation by the unfolded protein response. Int. Rev. Immunol. 30, 4-155
19. Grabiec, A. M., Tak, P. P., and Reedquist, K. A. (2011) Function of histone deacetylase inhibitors in inflammation. Crit. Rev. Immunol. 31, 233-2633
20. Belorgey, D., Irving, J. A., Ekeowa, U. I., Freeke, J., Roussel, B. D., Miranda, E., Pérez, J., Robinson, C. V., Marciniak, S. J., Crowther, D. C., Michel, C. H., and Lomas, D. A. (2011) Characterization of serpin polymers in vitro and in vivo. Methods 53, 255-2666
21. Singh, S., Vrishni, S., Singh, B. K., Rahman, I., and Kakkar, P. (2010) Nrf2-ARE stress response mechanism. A control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic. Res. 44, 1267-12888
22. Hutt, D. M., and Balch, W. E. (2012) Cold Spring Harb. Perspect. Biol., in presss
23. Oliveberg, M., and Wolynes, P. G. (2005) The experimental survey of protein-folding energy landscapes. Q. Rev. Biophys. 38, 245-2888
24. Eichner, T., and Radford, S. E. (2011)Adiversity of assembly mechanisms of a generic amyloid fold. Mol. Cell 43, 8-188
25. Lindquist, S. L., and Kelly, J. W. (2011) Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases. Progress and prognosis. Cold Spring Harb. Perspect. Biol. 3, a0045077
26. Kikis, E. A., Gidalevitz, T., and Morimoto, R. I. (2010) Protein homeostasis in models of aging and age-related conformational disease. Adv. Exp. Med. Biol. 694, 138-1599
27. Bouchecareilh, M., and Balch, W. E. (2012) Proteostasis, an emerging therapeutic paradigm for managing inflammatory airway stress disease. Curr. Mol. Med. 12, 815-8266
28. Sifers, R. N. (2010) Medicine. Clearing conformational disease. Science 329, 154-1555
29. Perlmutter, D. H., and Silverman, G. A. (2011) Hepatic fibrosis and carcinogenesis in α1-antitrypsin deficiency. A prototype for chronic tissue damage in gain-of-function disorders. Cold Spring Harb. Perspect. Biol. 3, a0058011
30. Flotte, T. R., and Mueller, C. (2011) Gene therapy for α1-antitrypsin deficiency. Hum. Mol. Genet. 20, R87-R922
31. Gooptu, B., Ekeowa, U. I., and Lomas, D. A. (2009) Mechanisms of emphysema in α1-antitrypsin deficiency. Molecular and cellular insights. Eur. Respir. J. 34, 475-4888
32. Ekeowa, U. I., Freeke, J., Miranda, E., Gooptu, B., Bush, M. F., Pérez, J., Teckman, J., Robinson, C. V., and Lomas, D. A. (2010) Defining the mechanism of polymerization in the serpinopathies. Proc. Natl. Acad. Sci. U.S.A. 107, 17146-171511
33. Ekeowa, U. I., Marciniak, S. J., and Lomas, D. A. (2011) α1-antitrypsin deficiency and inflammation. Expert Rev. Clin. Immunol. 7, 243-2522
34. Gooptu, B., and Lomas, D. A. (2009) Conformational pathology of the serpins. Themes, variations, and therapeutic strategies. Annu. Rev. Biochem. 78, 147-1766
35. Sifers, R. N. (2010) Intracellular processing of α1-antitrypsin. Proc. Am. Thorac. Soc. 7, 376-3800
36. Yamasaki, M., Sendall, T. J., Pearce, M. C., Whisstock, J. C., and Huntington, J. A. (2011) Molecular basis of α1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep. 12, 1011-10177
37. Stoller, J. K., and Aboussouan, L. S. (2012) A review of α1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 185, 246-2599
38. Kelly, E., Greene, C. M., Carroll, T. P., McElvaney, N. G., and O'Neill, S. J. (2010) α1-antitrypsin deficiency. Respir. Med. 104, 763-7722
39. Topic, A., Prokic, D., and Stankovic, I. (2011) α1-Antitrypsin deficiency in early childhood. Fetal Pediatr. Pathol. 30, 312-3199
40. Marciniak, S. J., and Lomas, D. A. (2010) α1-Antitrypsin deficiency and autophagy. N. Engl. J. Med. 363, 1863-18644
41. To, M., Yamamura, S., Akashi, K., Charron, C. E., Barnes, P. J., and Ito, K. (2012) Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. Chest 141, 1233-12422
42. Mizuno, S., Yasuo, M., Bogaard, H. J., Kraskauskas, D., Natarajan, R., and Voelkel, N. F. (2011) Inhibition of histone deacetylase causes emphysema. Am. J. Physiol. Lung Cell Mol. Physiol. 300, L402-L4133
43. Min, T., Bodas, M., Mazur, S., and Vij, N. (2011) Critical role of proteostasis. Imbalance in pathogenesis of COPD and severe emphysema. J. Mol. Med. 89, 577-5933
44. Mercado, N., Thimmulappa, R., Thomas, C. M., Fenwick, P. S., Chana, K. K., Donnelly, L. E., Biswal, S., Ito, K., and Barnes, P. J. (2011) Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 406, 292-2988
45. Isajevs, S., Taivans, I., Svirina, D., Strazda, G., and Kopeika, U. (2011) Patterns of inflammatory responses in large and small airways in smokers with and without chronic obstructive pulmonary disease. Respiration 81, 362-3711
46. Banerjee, A., Trivedi, C. M., Damera, G., Jiang, M., Jester, W., Hoshi, T., Epstein, J. A., and Panettieri, R. A., Jr. (2012) Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models. Am. J. Respir. Cell Mol. Biol. 46, 132-1388
47. Hutt, D. M., Herman, D., Rodrigues, A. P., Noel, S., Pilewski, J. M., Matteson, J., Hoch, B., Kellner, W., Kelly, J. W., Schmidt, A., Thomas, P. J., Matsumura, Y., Skach, W. R., Gentzsch, M., Riordan, J. R., Sorscher, E. J., Okiyoneda, T., Yates, J. R., 3rd, Lukacs, G. L., Frizzell, R. A., Manning, G., Gottesfeld, J. M., and Balch, W. E. (2010) Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 6, 25-333
48. Chung, K. F., and Marwick, J. A. (2010) Molecular mechanisms of oxidative stress in airways and lungs with reference to asthma and chronic obstructive pulmonary disease. Ann. N.Y. Acad. Sci. 1203, 85-911
49. Rajendrasozhan, S., Yao, H., and Rahman, I. (2009) Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD. COPD 6, 291-2977
50. Peserico, A., and Simone, C. (2011) Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J Biomed. Biotechnol. 2011, 3718322
51. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., and Mann, M. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-8400
52. Mollapour, M., and Neckers, L. (2012) Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim. Biophys. Acta 1823, 648-6555
53. Cook, C., and Petrucelli, L. (2012) Tau triage decisions mediated by the chaperone network. J. Alzheimers Dis., in presss
54. Kekatpure, V. D., Dannenberg, A. J., and Subbaramaiah, K. (2009) HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem. 284, 7436-74455
55. Scroggins, B. T., Robzyk, K., Wang, D., Marcu, M. G., Tsutsumi, S., Beebe, K., Cotter, R. J., Felts, S., Toft, D., Karnitz, L., Rosen, N., and Neckers, L. (2007) An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25, 151-1599
56. Murphy, P. J., Morishima, Y., Kovacs, J. J., Yao, T. P., and Pratt, W. B. (2005) Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem. 280, 33792-337999
57. Zeng, L., Chen, R., Liang, F., Tsuchiya, H., Murai, H., Nakahashi, T., Iwai, K., Takahashi, T., Kanda, T., and Morimoto, S. (2009) Silent information regulator, Sirtuin 1, and age-related diseases. Geriatr. Gerontol. Int. 9, 7-155
58. Westerheide, S. D., Anckar, J., Stevens, S. M., Jr., Sistonen, L., and Morimoto, R. I. (2009) Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323, 1063-10666
59. Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., and Hotamisligil, G. S. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-11400
60. Christensen, D. P., Dahllöf, M., Lundh, M., Rasmussen, D. N., Nielsen, M. D., Billestrup, N., Grunnet, L. G., and Mandrup-Poulsen, T. (2011) Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med. 17, 378-3900
61. Leggatt, G. R., and Gabrielli, B. (2012) Histone deacetylase inhibitors in the generation of the anti-tumor immune response. Immunol. Cell Biol. 90, 33-388
62. Marks, P. A. (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 19, 1049-10666
63. Jagannath, S., Dimopoulos, M. A., and Lonial, S. (2010) Combined proteasome and histone deacetylase inhibition. A promising synergy for patients with relapsed/refractory multiple myeloma. Leuk. Res. 34, 1111-11188
64. Buckland, J. (2011) Rheumatoid arthritis, HDAC and HDACi, pathogenetic and mechanistic insights. Nat. Rev. Rheumatol. 7, 6822
65. Marwick, J. A., Ito, K., Adcock, I. M., and Kirkham, P. A. (2007) Oxidative stress and steroid resistance in asthma and COPD. pharmacological manipulation of HDAC-2 as a therapeutic strategy. Expert Opin. Ther. Targets 11, 745-7555
66. Halili, M. A., Andrews, M. R., Sweet, M. J., and Fairlie, D. P. (2009) Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 9, 309-3199
67. Marwick, J. A., Adcock, I. M., and Chung, K. F. (2010) Overcoming reduced glucocorticoid sensitivity in airway disease. Molecular mechanisms and therapeutic approaches. Drugs 70, 929-9488
68. Hutt, D. M., Olsen, C. A., Vickers, C. J., Herman, D., Chalfant, M., Montero, A., Leman, L. J., Burkle, R., Maryanoff, B. E., Balch, W. E., and Ghadiri, M. R. (2011) Potential agents for treating cystic fibrosis. Cyclic tetrapeptides that restore trafficking and activity of ΔF508-CFTR. ACS Med. Chem. Lett. 2, 703-7077
69. Lu, J., Yang, C., Chen, M., Ye, D. Y., Lonser, R. R., Brady, R. O., and Zhuang, Z. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl. Acad. Sci. U.S.A. 108, 21200-212055
70. Hageman, J., van Waarde, M. A., Zylicz, A., Walerych, D., and Kampinga, H. H. (2011) The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities. Biochem. J. 435, 127-1422
71. Pipalia, N. H., Cosner, C. C., Huang, A., Chatterjee, A., Bourbon, P., Farley, N., Helquist, P., Wiest, O., and Maxfield, F. R. (2011) Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 108, 5620-56255
72. Thomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K. M., Borok, J. F., Herman, D., Geschwind, D. H., and Gottesfeld, J. M. (2008) The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington disease transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 105, 15564-155699
73. Chuang, D. M., Leng, Y., Marinova, Z., Kim, H. J., and Chiu, C. T. (2009) Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32, 591-6011
74. Zhang, L. J., Liu, X., Gafken, P. R., Kioussi, C., and Leid, M. (2009) A chicken ovalbumin upstream promoter transcription factor I (COUPTFI) complex represses expression of the gene encoding tumor necrosis factor α-induced protein 8 (TNFAIP8). J. Biol. Chem. 284, 6156-61688
75. Shi, Y., Sawada, J., Sui, G., Affar el, B., Whetstine, J. R., Lan, F., Ogawa, H., Luke, M. P., and Nakatani, Y. (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422, 735-7388
76. Nakatani, Y., and Ogryzko, V. (2003) Immunoaffinity purification of mammalian protein complexes. Methods Enzymol. 370, 430-4444
77. Hathorn, T., Snyder-Keller, A., and Messer, A. (2011) Nicotinamide improves motor deficits and up-regulates PGC-1α and BDNF gene expression in a mouse model of Huntington disease. Neurobiol. Dis. 41, 43-500
78. Marks, P. A., and Dokmanovic, M. (2005) Histone deacetylase inhibitors. Discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497-15111
79. Blander, G., and Guarente, L. (2004) The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417-4355
80. Dokmanovic, M., Perez, G., Xu, W., Ngo, L., Clarke, C., Parmigiani, R. B., and Marks, P. A. (2007) Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther. 6, 2525-25344
81. Mielcarek, M., Benn, C. L., Franklin, S. A., Smith, D. L., Woodman, B., Marks, P. A., and Bates, G. P. (2011) SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington disease. PLoS One 6, e277466
82. Cameron, P. H., Chevet, E., Pluquet, O., Thomas, D. Y., and Bergeron, J. J. (2009) Calnexin phosphorylation attenuates the release of partially mis-folded α1-antitrypsin to the secretory pathway. J. Biol. Chem. 284, 34570-345799
83. Nyfeler, B., Reiterer, V., Wendeler, M. W., Stefan, E., Zhang, B., Michnick, S. W., and Hauri, H. P. (2008) Identification of ERGIC-53 as an intracellular transport receptor of α1-antitrypsin. J. Cell Biol. 180, 705-7122
84. Papp, E., Száraz, P., Korcsmáros, T., and Csermely, P. (2006) Changes of endoplasmic reticulum chaperone complexes, redox state, and impaired protein disulfide reductase activity in misfolding α1-antitrypsin transgenic mice. FASEB J. 20, 1018-10200
85. Graham, K. S., Le, A., and Sifers, R. N. (1990) Accumulation of the insoluble PiZ-variant of human α1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP. J. Biol. Chem. 265, 20463-204688
86. Shen, Y., Ballar, P., and Fang, S. (2006) Ubiquitin ligase gp78 increases solubility and facilitates degradation of the Z-variant of α1- antitrypsin. Biochem. Biophys. Res. Commun. 349, 1285-12933
87. Schmidt, B. Z., and Perlmutter, D. H. (2005) Grp78, Grp94, and Grp170 interact with α1-antitrypsin mutants that are retained in the endoplasmic reticulum. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G444-G4555
88. Norez, C., Noel, S., Wilke, M., Bijvelds, M., Jorna, H., Melin, P., DeJonge, H., and Becq, F. (2006) Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the α-glucosidase inhibitor miglustat. FEBS Lett. 580, 2081-20866
89. Cormier, J. H., Tamura, T., Sunryd, J. C., and Hebert, D. N. (2009) EDEM1 recognition and delivery of misfolded proteins to the SEL1Lcontaining ERAD complex. Mol. Cell 34, 627-6333
90. Pan, S., Wang, S., Utama, B., Huang, L., Blok, N., Estes, M. K., Moremen, K. W., and Sifers, R. N. (2011) Golgi localization of ERManI defines spatial separation of the mammalian glycoprotein quality control system. Mol. Biol. Cell 22, 2810-28222
91. Marcus, N. Y., and Perlmutter, D. H. (2000) Glucosidase and mannosidase inhibitors mediate increased secretion of mutant α1-antitrypsin Z. J. Biol. Chem. 275, 1987-19922
92. Reiterer, V., Nyfeler, B., and Hauri, H. P. (2010) Role of the lectin VIP36 in post-ER quality control of human α1-antitrypsin. Traffic 11, 1044-10555
93. Cabral, C. M., Liu, Y., Moremen, K. W., and Sifers, R. N. (2002) Organizational diversity among distinct glycoprotein endoplasmic reticulumassociated degradation programs. Mol. Biol. Cell 13, 2639-26500
94. Hirao, K., Natsuka, Y., Tamura, T., Wada, I., Morito, D., Natsuka, S., Romero, P., Sleno, B., Tremblay, L. O., Herscovics, A., Nagata, K., and Hosokawa, N. (2006) EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J. Biol. Chem. 281, 9650-96588
95. Christianson, J. C., Shaler, T. A., Tyler, R. E., and Kopito, R. R. (2008) OS-9 and GRP94 deliver mutantα1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD. Nat. Cell Biol. 10, 272-2822
96. Burrows, J. A., Willis, L. K., and Perlmutter, D. H. (2000) Chemical chaperones mediate increased secretion of mutantα 1-antitrypsin (α1-AT) Z. A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency. Proc. Natl. Acad. Sci. U.S.A. 97, 1796-18011
97. Aka, J. A., Kim, G. W., and Yang, X. J. (2011) K-acetylation and its enzymes. Overview and new developments. Handb. Exp. Pharmacol. 206, 1-122
98. Gnad, F., Ren, S., Choudhary, C., Cox, J., and Mann, M. (2010) Predicting post-translational lysine acetylation using support vector machines. Bioinformatics 26, 1666-16688
99. Galli, C., Bernasconi, R., Soldà, T., Calanca, V., and Molinari, M. (2011) Malectin participates in a backup glycoprotein quality control pathway in the mammalian ER. PLoS One 6, e163044
100. Hosokawa, N., Wada, I., Natsuka, Y., and Nagata, K. (2006) EDEM accelerates ERAD by preventing aberrant dimer formation of misfolded α1-antitrypsin. Genes Cells 11, 465-4766
101. Oda, Y., Hosokawa, N., Wada, I., and Nagata, K. (2003) EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin. Science 299, 1394-13977
102. Kahali, S., Sarcar, B., Prabhu, A., Seto, E., and Chinnaiyan, P. (2012) Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASEB J. 26, 2437-24455
103. Alam, S., Wang, J., Janciauskiene, S., and Mahadeva, R. (2012) Preventing and reversing the cellular consequences of Z α1-antitrypsin accumulation by targeting s4A. J. Hepatol. 57, 116-1244
104. Hidvegi, T., Mukherjee, A., Ewing, M., Kemp, C., and Perlmutter, D. H. (2011) The role of autophagy in α1-antitrypsin deficiency. Methods Enzymol. 499, 33-544
105. Hidvegi, T., Ewing, M., Hale, P., Dippold, C., Beckett, C., Kemp, C., Maurice, N., Mukherjee, A., Goldbach, C., Watkins, S., Michalopoulos, G., and Perlmutter, D. H. (2010) An autophagy-enhancing drug promotes degradation of mutant α1-antitrypsin Z and reduces hepatic fibrosis. Science 329, 229-2322
106. Kaushal, S., Annamali, M., Blomenkamp, K., Rudnick, D., Halloran, D., Brunt, E. M., and Teckman, J. H. (2010) Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp. Biol. Med. (Maywood) 235, 700-7099
107. Ogushi, F., Fells, G. A., Hubbard, R. C., Straus, S. D., and Crystal, R. G. (1987) Z-type α1-antitrypsin is less competent than M1-type α1-antitrypsin as an inhibitor of neutrophil elastase. J. Clin. Invest. 80, 1366-13744
108. Pan, S., Huang, L., McPherson, J., Muzny, D., Rouhani, F., Brantly, M., Gibbs, R., and Sifers, R. N. (2009) Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in α1-antitrypsin deficiency. Hepatology 50, 275-2811
109. Mast, S. W., Diekman, K., Karaveg, K., Davis, A., Sifers, R. N., and Moremen, K. W. (2005) Human EDEM2, a novel homolog of family 47 glycosidases, is involved in ER-associated degradation of glycoproteins. Glycobiology 15, 421-4366
110. Gosai, S. J., Kwak, J. H., Luke, C. J., Long, O. S., King, D. E., Kovatch, K. J., Johnston, P. A., Shun, T. Y., Lazo, J. S., Perlmutter, D. H., Silverman, G. A., and Pak, S. C. (2010) Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS One 5, e154600
111. Yi, C., Ma, M., Ran, L., Zheng, J., Tong, J., Zhu, J., Ma, C., Sun, Y., Zhang, S., Feng, W., Zhu, L., Le, Y., Gong, X., Yan, X., Hong, B., Jiang, F. J., Xie, Z., Miao, D., Deng, H., and Yu, L. (2012) Function and molecular mechanism of acetylation in autophagy regulation. Science 336, 474-4777